Correlation Between Cerebral Oxygenation and Neurodevelopment in VLBW Preterm Infants.

April 3, 2017 updated by: Luigi Corvaglia, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Correlation Between Neonatal Cerebral Oxygenation and Later Psychomotor Outcome in Very-low-birth-weight Preterm Infants.

The recent improvements in neonatal intensive care have led to a substantial increase in the survival rate of preterm infants; nevertheless, this population is still at high risk for long-term neurodevelopmental disabilities. Significant anatomical changes in brain structures and abnormal patterns of neuronal myelination and brain connectivity have been associated with preterm birth, with possible long-term effects on cognitive, motor and social skills.

The validation of clinical tools able to predict neurodevelopmental outcomes in the preterm population might help at identifying infants at greatest risk of impairment, who would benefit most from early supportive interventions exploiting brain neuroplasticity.

Near infrared reflected spectroscopy (NIRS) provides a bedside, non-invasive, continuous monitoring of cerebral oxygen saturation (CrSO2), which has been proposed as a predictive marker for later neurodevelopment in neonates undergone cardiac surgery; to date, however, evidence on the correlation between CrSO2 and later neurodevelopment in preterm infants is almost lacking.

This study aims to evaluate whether CrSO2 monitoring, performed before NICU discharge in clinically stable very low birth weight (VLBW) preterm infants, can predict psychomotor outcomes during the first 24 months of corrected age (ca).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The improvements in neonatal intensive care occurred over the last decades have led to a substantial increase in the survival rate of preterm infants, especially of extremely low birth weight. Nevertheless, the delicate maturation of central nervous system (CNS) in the extrauterine environment, together with the possible development of prematurity-related clinical complications that could result in brain injury, place this population at high risk for long-term neurodevelopmental disabilities.

Significant anatomical changes in brain structures have been associated with preterm birth; among these, enlarged ventricles and subarachnoid spaces, reduced subcortical white matter and decreased cortical and deep nuclear grey matter are the most common. Additionally, there is increasing evidence of abnormal patterns of neuronal myelination and brain connectivity in preterm infants, with possible concerning long-term effects on language, motor and social skills. As for cognitive abilities, a direct correlation with gestational age (GA) has been previously shown in a large cohort of preterm born children at school age.

In its early phases, the developmental of CNS is characterized by an intrinsic neuroplasticity, according which repeated experiences could influence the arrangement of synaptic connections and neural circuitries, thus resulting in structural and functional changes. By exploiting this feature, an early establishment of supportive interventions¬ might aid to compensate the anatomical and functional constraints connected to preterm birth and to improve preterm infants' neurodevelopment.

The validation of clinical tools able to predict neurodevelopmental outcomes in the preterm population might help at identifying infants at greatest risk of impairment, who would benefit most from early rehabilitative interventions. Near infrared reflected spectroscopy (NIRS) provides a bedside, non-invasive, continuous monitoring of cerebral oxygen saturation (CrSO2) and has been largely adopted to assess neonatal brain oxygenation and perfusion in intensive care settings. Perioperative CrSO2 has been recently proposed as a possible predictor of later neurodevelopmental outcomes in neonates undergone cardiac surgery; data evaluating the correlation between CrSO2 and later neurodevelopment in preterm infants, however, are very scarce and limited to the first days of life; at this time, CrSO2 can be widely influenced by the occurrence of systemic haemodynamic instability and is blind to several clinical complications, known as potential causes of brain damage, that can occur later on during hospital stay and thus are not necessarily directly related to changes in cerebral oxygenation within the first days of life (e.g. necrotizing enterocolitis [NEC], late onset sepsis).

Hence, the aim of this study was to evaluate whether CrSO2 monitoring, performed before NICU discharge in clinically stable very low birth weight (VLBW) preterm infants, can predict psychomotor outcomes during the first 24 months of corrected age (ca).

Infants meeting eligibility criteria (for details see specific section) undergo a 3-hour continuous monitoring of CrSO2 by means of the INVOS 5100 oximeter when satisfying the following condition: stable clinical condition, no need for oxygen supplementation, full enteral feeding (defined as 160 ml/kg/day) After discharge, the enrolled infants are included in a long-term neurodevelopmental follow-up, which is part of the normal routine care for preterm-born infants and aims at the early identification and treatment of neurocognitive sequelae possibly related to preterm birth.

In this context, psychomotor outcome (PSO) is assessed at 6, 12, 18 and 24 months ca by means of the Griffiths Mental Development Scales 0-2 years [26]. These scales investigate five main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each of the developmental areas.

The Griffiths Scales are administered individually, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent.

A correlation analysis between mean CrSO2 values and GQ/SQ scores at each follow-up appointment will be performed. In order to evaluate the effect of possible confounding variables on the observed results, a mixed model including a number of risk factors known to affect preterm infants' neurodevelopment will be built for hierarchical multiple regression analysis. Significance level will be set at p<0.05.

Study Type

Observational

Enrollment (Actual)

63

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
    • BO
      • Bologna, BO, Italy, 40138
        • U.O. Neonatologia, Day Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 8 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Preterm infants admitted to the Neonatal Intensive Care Unit (NICU) of St. Orsola-Malpighi Hospital, Bologna (Italy) fulfilling the eligibility criteria.

Description

Inclusion Criteria:

  • gestational age <32 weeks
  • birth weight <1500 g.

Exclusion Criteria:

  • congenital abnormalities
  • hypoxic-ischemic encephalopathy
  • intraventricular haemorrhage grade 3-4
  • post-haemorrhagic ventricular dilatation
  • periventricular leukomalacia and/or porencephalic cysts
  • general anaesthesia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Psychomotor outcome
Time Frame: 24 months
Psychomotor outcome is assessed by Griffiths Mental Development Scales 0-2 years. Psychomotor outcome is considered normal if DQ>88.6; lower values characterize psychomotor impairment, which is further defined as mild (-1 to -2 SD, corresponding to 88.6-76.9 DQ), moderate (-2 to -3 SD, corresponding to 76.8- 65.1 DQ) and severe (<-3 SD, corresponding to 65 DQ).
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2013

Primary Completion (Actual)

December 31, 2016

Study Completion (Actual)

December 31, 2016

Study Registration Dates

First Submitted

April 3, 2017

First Submitted That Met QC Criteria

April 3, 2017

First Posted (Actual)

April 7, 2017

Study Record Updates

Last Update Posted (Actual)

April 7, 2017

Last Update Submitted That Met QC Criteria

April 3, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SO-2016-GQ
  • PRET_01_13 (Other Identifier: Ethic Committee of St. Orsola-Malpighi University Hospital)
  • NIRS-SO (Other Identifier: Ethic Committee of St. Orsola-Malpighi University Hospital)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychomotor Impairment

Clinical Trials on Griffiths Mental Development Scales

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe